S7 Table. Adverse events regardless of study drug relationship (occurring in  $\geq$  35% of the total patients) by preferred term, maximum grade, and treatment arm

Category	450-mg Fed	600-mg Fed	750-mg Fasted	Total
	(n=29)	(n=19)	(n=26)	(n=74)
Total				
Any-grade AEs	29 (100)	18 (94.7)	26 (100)	73 (98.6)
Grade 3/4	21 (72.4)	15 (78.9)	17 (65.4)	53 (71.6)
Diarrhea				
Any grade	20 (69.0)	12 (63.2)	19 (73.1)	51 (68.9)
Grade 3/4	0	0	2 (7.7)	2 (7.7)
Increased ALT				
Any grade	18 (62.1)	12 (63.2)	12 (46.2)	42 (56.8)
Grade 3/4	8 (27.6)	7 (36.8)	8 (30.8)	23 (31.1)
Vomiting				
Any grade	15 (51.7)	7 (36.8)	19 (73.1)	41 (55.4)
Grade 3/4	1 (3.4)	0	0	1 (1.4)
Increased AST				
Any grade	17 (58.6)	10 (52.6)	9 (34.6)	36 (48.6)
Grade 3/4	5 (17.2)	5 (26.3)	4 (15.4)	14 (18.9)
Nausea				
Any grade	10 (34.5)	11 (57.9)	14 (53.8)	35 (47.3)
Grade 3/4	0	1 (5.3)	0	1 (1.4)
<b>Increased GGT</b>				
Any grade	12 (41.4)	4 (21.1)	7 (26.9)	23 (31.1)
Grade 3/4	9 (31.0)	2 (10.5)	3 (11.5)	14 (18.9)
Abdominal pain				
Any grade	9 (31.0)	4 (21.1)	8 (30.8)	21 (68.4)
Grade 3/4	0	0	0	0

Values are presented as number (%). AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.